Dr. Christine Eischen, the Herbert A. Rosenthal, MD Professor of Medical Oncology, and Biochemistry & Molecular Biology, has been awarded a $100,000 research grant from the Pennsylvania Breast Cancer Coalition to advance targeted therapeutic strategies for triple-negative breast cancer. Dr. Eischen’s research focuses on a critical molecular vulnerability in triple-negative breast cancer: the dependence of p53-mutated cancer cells on the MDM2 protein for survival. The grant will support Dr. Eischen’s laboratory, which employs innovative Proteolysis Targeting Chimera (“PROTAC”) technology to facilitate the degradation of MDM2 while simultaneously investigating potential mechanisms of treatment resistance. These grants play a vital role in advancing breast cancer research—particularly in the areas of early detection, treatment approaches, and improved patient outcomes.
Christine Eischen, PhD Receives Breast Cancer Research Grant
